Home
Report Store
Bipolar Depression Market Insight, Epidemiology And Market Forecast - 2032

Bipolar Depression Market Insight, Epidemiology And Market Forecast - 2032

Published Date:

Jan 2022

Pages:

200

Delivery Time:

7-10 Business Days

Region:

United States,EU5,Japan

Bipolar Depression Market

Key Highlights:

In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM.
Bipolar Disorder companies working in the market are Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others

Request a sample to unlock the CAGR for Bipolar Depression Market.

DelveInsight's "Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Bipolar Depression market report provides current treatment practices, emerging drugs, Bipolar Depression (Manic Depression) market share of the individual therapies, current and forecasted Bipolar Depression market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Bipolar Depression market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

Bipolar Depression (Manic Depression) Disease Understanding and Treatment Algorithm

Bipolar Depression, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS); the classification is based on the characteristics of mood swings.

Bipolar Depression Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Bipolar Depression (Manic Depression).

Bipolar Depression Treatment

It covers the details of conventional and current medical therapies available in the Bipolar Depression market for the treatment of the condition. It also provides Bipolar Depression (Manic Depression) treatment algorithms and guidelines in the United States, Europe, and Japan.

Bipolar Depression Epidemiology

The Bipolar Depression epidemiology section provides insights about the historical and current Bipolar Depression (Manic Depression) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Bipolar Depression market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM.

Country Wise- Bipolar Depression Epidemiology

The epidemiology segment also provides the Bipolar Depression epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

In the United States, the total number of diagnosed Bipolar Depression prevalent cases was 2,401,287 cases in the year 2020.
In the year 2020, the total diagnosed Bipolar Depression prevalent cases were 1,004,168 cases in EU-5.
In Japan, the total number of diagnosed Bipolar Depression prevalent cases were 146,621 cases in the year 2020.

Bipolar Depression Drug Chapters

The drug chapter segment of the Bipolar Depression report encloses the detailed analysis of Bipolar Depression marketed drugs and late-stage (Phase-III and Phase-II) Bipolar Depression pipeline drugs. It also helps to understand the Bipolar Depression clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Bipolar Depression Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Bipolar Depression treatment.

Bipolar Depression Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Bipolar Depression treatment.

Bipolar Depression Market Outlook

The Bipolar Depression market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Bipolar Depression market trends by analyzing the impact of current Bipolar Depression therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Bipolar Depression market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Bipolar Depression market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Bipolar Depression market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Bipolar Depression market in 7MM.

The United States Bipolar Depression Market Outlook

This section provides the total Bipolar Depression market size and market size by therapies in the United States.

EU-5 Countries: Bipolar Depression Market Outlook

The total Bipolar Depression market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Bipolar Depression market size and market size by therapies in Japan is also mentioned.

Bipolar Depression Drugs Uptake

This section focuses on the rate of uptake of the potential Bipolar Depression drugs recently launched in the Bipolar Depression market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Bipolar Depression market uptake by drugs; patient uptake by therapies; and sales of each drug.

Bipolar Depression Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Bipolar Depression market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Bipolar Depression (Manic Depression) Pipeline Development Activities

The Bipolar Depression (Manic Depression) report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Bipolar Depression (Manic Depression) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The drugs which are in pipeline include:

Lumateperone/ITI-007 (Intra-Cellular Therapies)
SEP-4199 (Sunovion/Sumitomo Dainippon Pharma)
NRX-100/NRX-101 (NeuroRx)
Psilocybin (COMPASS Pathways)
Brexpiprazole (Lundbeck/Otsuka Pharmaceutical)
Falkieri (Celon Pharma)

Reimbursement Scenario in Bipolar Depression

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Bipolar Depression market trends, we take KOLs and SMEs ' opinion working in the Bipolar Depression domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Bipolar Depression market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Bipolar Depression (Manic Depression) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics	Details
Study Period	2019 to 2032
Base Year	2021
Forecast Period	2022 to 2032
CAGR	*Request Sample to Know*
Market Size	*USD XX million in 2021*
Key Companies	Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others

Scope of the Bipolar Depression Market Report

The report covers the descriptive overview of Bipolar Depression (Manic Depression), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Bipolar Depression epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Bipolar Depression (Manic Depression) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Bipolar Depression market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bipolar Depression market

Bipolar Depression Market Report Highlights

In the coming years, the Bipolar Depression market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Bipolar Depression. The launch of emerging therapies will significantly impact the Bipolar Depression market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bipolar Depression
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Bipolar Depression Market Report Insights

Bipolar Depression Patient Population
Therapeutic Approaches
Bipolar Depression Pipeline Analysis
Bipolar Depression Market Size and Trends
Bipolar Depression Market Opportunities
Impact of upcoming Bipolar Depression Therapies

Bipolar Depression Market Report Key Strengths

11 Years Forecast
7MM Coverage
Bipolar Depression Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Bipolar Depression Market Report Assessment

Current Treatment Practices
Unmet Needs
Bipolar Depression Pipeline Product Profiles
Bipolar Depression Market Attractiveness
Bipolar Depression Market Drivers
Bipolar Depression Market Barriers

Key Questions

Market Insights:

What was the Bipolar Depression drug class share (%) distribution in 2019 and how it would look like in 2032?
What would be the total Bipolar Depression market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Bipolar Depression market size during the forecast period (2019-2032)?
At what CAGR, the Bipolar Depression market is expected to grow by 7MM during the forecast period (2019-2032)?
What would be the Bipolar Depression market outlook across the 7MM during the forecast period (2019-2032)?
What would be the Bipolar Depression market growth till 2032, and what will be the resultant market Size in the year 2032?
How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burden, and regional/ethnic differences of the Bipolar Depression (Manic Depression)?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical Bipolar Depression (Manic Depression) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Bipolar Depression (Manic Depression) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Bipolar Depression (Manic Depression)?
Out of all 7MM countries, which country would have the highest prevalent population of Bipolar Depression (Manic Depression) during the forecast period (2019-2032)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Bipolar Depression (Manic Depression) treatment in addition to the approved therapies?
What are the current treatment guidelines for the treatment of Bipolar Depression (Manic Depression) in the USA, Europe, and Japan?
What are the Bipolar Depression marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Bipolar Depression?
How many therapies are in-development by each company for Bipolar Depression treatment?
How many are emerging therapies in mid-stage, and late stage of development for Bipolar Depression treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Bipolar Depression therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Bipolar Depression (Manic Depression) and their status?
What are the current challenges faced in drug development?
What are the key designations that have been granted for the emerging therapies for Bipolar Depression (Manic Depression)?
What are the global historical and forecasted market of Bipolar Depression (Manic Depression)?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Bipolar Depression market
To understand the future market competition in the Bipolar Depression market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Bipolar Depression (Manic Depression) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Bipolar Depression market
To understand the future market competition in the Bipolar Depression market

Frequently Asked Questions

What is Bipolar Depression?

Bipolar Depression, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed).

What is the Bipolar Depression Market Size in 7MM?

The total Bipolar Depression market size was accounted for USD XXXX Million in the year 2021 and is estimated to grow during the study period (2019-2032).

Who are the leading companies in the Bipolar Depression Market Landscape?

The key players in the Bipolar Depression market who are in different phases of developing Bipolar Depression Therapies are Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others.

What are the Key strengths of the Bipolar Depression Market Report?

Key strengths of the Bipolar Depression Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Bipolar Depression Market.

Which country is expected to account for the most significant prevalent cases for Bipolar Depression in the 7MM?

The United States is expected to account for the highest prevalent Bipolar Depression cases..

1. Key Insights

2. Executive Summary of Bipolar Depression (Manic Depression)

3. Competitive Intelligence Analysis for Bipolar Depression (Manic Depression)

4. Bipolar Depression Market Overview at a Glance

4.1. Bipolar Depression Total Market Share (%) Distribution in 2019

4.2. Bipolar Depression Total Market Share (%) Distribution in 2032

5. Bipolar Depression (Manic Depression): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Bipolar Depression (Manic Depression) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Bipolar Depression (Manic Depression) Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Bipolar Depression (Manic Depression) Treatment and Management

8.2. Bipolar Depression (Manic Depression) Treatment Algorithm

9. Bipolar Depression Unmet Needs

10. Key Endpoints of Bipolar Depression Treatment

11. Bipolar Depression Marketed Products

11.1. List of Bipolar Depression Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Bipolar Depression (Manic Depression) Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Bipolar Depression (Manic Depression): Seven Major Market Analysis

13.1. Key Findings

13.2. Bipolar Depression Market Size in 7MM

13.3. Bipolar Depression Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Bipolar Depression Total Market Size in the United States

15.1.2. Bipolar Depression Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Bipolar Depression Total Market Size in Germany

15.3.2. Bipolar Depression Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Bipolar Depression Total Market Size in France

15.4.2. Bipolar Depression Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Bipolar Depression Total Market Size in Italy

15.5.2. Bipolar Depression Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Bipolar Depression Total Market Size in Spain

15.6.2. Bipolar Depression Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Bipolar Depression Total Market Size in the United Kingdom

15.7.2. Bipolar Depression Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Bipolar Depression Total Market Size in Japan

15.8.3. Bipolar Depression Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Bipolar Depression (Manic Depression)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary

List of Table

Table 1: 7MM Bipolar Depression (Manic Depression) Epidemiology (2019-2032)

Table 2: 7MM Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases (2019-2032)

Table 3: Bipolar Depression (Manic Depression) Epidemiology in the United States (2019-2032)

Table 4: Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Bipolar Depression (Manic Depression) Epidemiology in Germany (2019-2032)

Table 6: Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Bipolar Depression (Manic Depression) Epidemiology in France (2019-2032)

Table 8: Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Bipolar Depression (Manic Depression) Epidemiology in Italy (2019-2032)

Table 10: Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Bipolar Depression (Manic Depression) Epidemiology in Spain (2019-2032)

Table 12: Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Bipolar Depression (Manic Depression) Epidemiology in the UK (2019-2032)

Table 14: Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Bipolar Depression (Manic Depression) Epidemiology in Japan (2019-2032)

Table 16: Bipolar Depression (Manic Depression) Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary